Market Cap 2.43B
Revenue (ttm) 51.95M
Net Income (ttm) -265.94M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -511.92%
Debt to Equity Ratio 0.14
Volume 3,051,300
Avg Vol 2,843,942
Day's Range N/A - N/A
Shares Out 219.62M
Stochastic %K 74%
Beta 0.93
Analysts Strong Sell
Price Target $26.73

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Address:
14 Crosby Drive, 3rd Floor, Bedford, United States
highkick
highkick Aug. 24 at 3:40 PM
$OCUL 11k 9$ puts and 12k 11 $ calls for September 18th coming into play ?
0 · Reply
DrKyle
DrKyle Aug. 24 at 3:30 PM
$OCUL pending legal investigation into Eyepoint Pharmaceuticals https://www.globenewswire.com/news-release/2026/08/24/3349866/3080/en/levi-korsinsky-notifies-investors-of-pending-investigation-into-securities-claims-involving-eyepoint-pharmaceuticals-eypt.html
1 · Reply
MaxKlim
MaxKlim Aug. 24 at 3:11 PM
$OCUL time to add
0 · Reply
Tmoney85285
Tmoney85285 Aug. 24 at 3:07 PM
$OCUL hahahahahahahhaaha
0 · Reply
Tmoney85285
Tmoney85285 Aug. 24 at 1:52 PM
$OCUL hahahaha well deserved you losers. TKIs work about as well as JJ on a diet! LMAO
1 · Reply
Kashking03
Kashking03 Aug. 24 at 10:47 AM
$OCUL does this brk 12$ this week or dip to single digit 🫣 @ShortSuckieTuckie @Harvo
2 · Reply
Aaronpell
Aaronpell Aug. 24 at 3:50 AM
0 · Reply
esu89
esu89 Aug. 23 at 10:53 PM
$OCUL for all those waiting for a buyout, IMO, it ain’t happening soon. I believe that this Board and management team and their investment, financial and legal advisers are shooting for the stars. I think they feel really strong about and are very confident in what they have. They are going to commercialize Axpaxli for wetAMD, start selling it and wait for the for the top line results from NPDR phase 3 before they would get the kind of interest they think they deserve. That being said, I think they have to give strong consideration right now to anything at $6 billion or more. What I think they are really looking for is $10 to $15 billion in the back half of 2027 or beyond. The real question for each investor is what their objective is. Anyone that doesn’t have an objective and sale plan right now is foolish IMO. As to an international partnership(s), not a chance unless all prospects of being acquired disappear. Just my thoughts.
2 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Aug. 23 at 5:45 PM
$OCUL Important events as I see it coming down the road 1. Filing of the NDA with the added SOL-R interim safety data which will include some redosed patients. If we get the "no new or unexpected safety events were identified in the Sol-R safety data" that is an important de-risking event regarding redosing. 2. SOL-1 2-year safety extension study mid 2027 adds to the data more redosing patients to give the FDA a level of comfort with redosing on the label. 3. SOL-R in mid 2028 which "could" give Axpaxli a superiority label versus Eylea HD. Looking at SOL-1 and Pulsar data, I feel pretty good about this happening. The genius of extending this trial puts the last data point at a few weeks before the next scheduled injection. I could be wrong, but given Pravin's comment that SOL-R is needed for ExUS markets, I would place the chances of an acquisition ahead of a ExUS Partnership with significant CVR's for SOL-R and Helios3. Then again, what's $350M for big pharma.
3 · Reply
Kashking03
Kashking03 Aug. 22 at 11:00 PM
$OCUL Summary of $OCUL piper discussion: > what about $EYPT Failed study move on > well could there be any relation to GA or glaucoma? Impossible, without a shadow of doubt > how does it affect you? We are better in every dimension across every parameter > guidance for your upcoming data or margin on effect or other parameters It will succeed but no guidance If ocular every does not hit a trial endpoint or faces bad clinical results, I hope they approach it to the bar that they are holding $EYPT to I am no expert in retinal diseases, and I also share the view that excluding outliers in such a trial is not a viable approach, but I am curious what association if any is there between tki in this setting and GA and glaucoma.
0 · Reply
Latest News on OCUL
Ocular Therapeutix rises 10.4%

2026-08-17T14:05:49.000Z - 7 days ago

Ocular Therapeutix rises 10.4%


Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)

2026-08-03T11:30:55.000Z - 21 days ago

Ocular Therapeutix reports Q2 EPS (35c), consensus (39c)


Ocular Therapeutix Earnings release: Q2 2026

Aug 3, 2026, 7:00 AM EDT - 21 days ago

Ocular Therapeutix Earnings release: Q2 2026


Ocular Therapeutix Quarterly report: Q2 2026

Aug 3, 2026, 7:00 AM EDT - 21 days ago

Ocular Therapeutix Quarterly report: Q2 2026


Ocular Therapeutix Slides: Study Result presentation

Aug 2, 2026, 7:00 AM EDT - 22 days ago

Ocular Therapeutix Slides: Study Result presentation


Ocular Therapeutix Slides: Study result presentation

Jul 16, 2026, 7:00 AM EDT - 5 weeks ago

Ocular Therapeutix Slides: Study result presentation


Ocular Therapeutix price target raised to $30 from $24 at Baird

2026-06-18T10:31:11.000Z - 2 months ago

Ocular Therapeutix price target raised to $30 from $24 at Baird


Ocular Therapeutix Transcript: Investor Day 2026

Jun 17, 2026, 2:00 PM EDT - 2 months ago

Ocular Therapeutix Transcript: Investor Day 2026


Ocular Therapeutix Press release: FY 2026

Jun 17, 2026, 2:00 PM EDT - 2 months ago

Ocular Therapeutix Press release: FY 2026


Ocular Therapeutix Slides: FY 2026

Jun 17, 2026, 2:00 PM EDT - 2 months ago

Ocular Therapeutix Slides: FY 2026


Ocular Therapeutix trading resumes

2026-06-17T13:15:09.000Z - 2 months ago

Ocular Therapeutix trading resumes


Ocular Therapeutix to resume trading at 9:15 am ET

2026-06-17T12:56:01.000Z - 2 months ago

Ocular Therapeutix to resume trading at 9:15 am ET


Ocular Therapeutix trading halted, news pending

2026-06-17T12:40:11.000Z - 2 months ago

Ocular Therapeutix trading halted, news pending


Ocular Therapeutix Transcript: AGM 2026

Jun 10, 2026, 8:30 AM EDT - 2 months ago

Ocular Therapeutix Transcript: AGM 2026


Ocular Therapeutix™ to Host Investor Day on June 17, 2026

Jun 2, 2026, 7:00 AM EDT - 2 months ago

Ocular Therapeutix™ to Host Investor Day on June 17, 2026


Ocular Therapeutix Slides: FY 2026

May 15, 2026, 7:00 AM EDT - 3 months ago

Ocular Therapeutix Slides: FY 2026


Ocular Therapeutix Earnings Call Transcript: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Ocular Therapeutix Earnings Call Transcript: Q1 2026


Ocular Therapeutix Earnings release: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Ocular Therapeutix Earnings release: Q1 2026


Ocular Therapeutix Quarterly report: Q1 2026

May 5, 2026, 8:00 AM EDT - 3 months ago

Ocular Therapeutix Quarterly report: Q1 2026


Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

2026-05-05T11:59:32.000Z - 3 months ago

Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)


Ocular Therapeutix Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Ocular Therapeutix Proxy statement: Proxy filing


Ocular Therapeutix Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

Ocular Therapeutix Proxy statement: Proxy filing


Ocular Therapeutix enrolls first patient in Axpali trial

2026-04-29T13:00:19.000Z - 4 months ago

Ocular Therapeutix enrolls first patient in Axpali trial


Ocular Therapeutix Transcript: HCW @ Home

Apr 27, 2026, 2:30 PM EDT - 4 months ago

Ocular Therapeutix Transcript: HCW @ Home


Ocular Therapeutix reports additional Axpaxli trial data

2026-04-13T11:22:45.000Z - 4 months ago

Ocular Therapeutix reports additional Axpaxli trial data


Ocular Therapeutix price target raised to $27 from $24 at BofA

2026-03-03T11:45:13.000Z - 6 months ago

Ocular Therapeutix price target raised to $27 from $24 at BofA


Ocular Therapeutix Transcript: Study update

Mar 2, 2026, 7:30 AM EST - 6 months ago

Ocular Therapeutix Transcript: Study update


Ocular Therapeutix Transcript: Study result

Feb 17, 2026, 8:00 AM EST - 6 months ago

Ocular Therapeutix Transcript: Study result


Ocular Therapeutix Press release: Study result

Feb 17, 2026, 8:00 AM EST - 6 months ago

Ocular Therapeutix Press release: Study result


Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)

2026-02-05T12:05:13.000Z - 7 months ago

Ocular Therapeutix reports Q4 EPS (29c), consensus (34c)


Ocular Therapeutix Annual report: Q4 2025

Feb 5, 2026, 7:00 AM EST - 7 months ago

Ocular Therapeutix Annual report: Q4 2025


Ocular Therapeutix Earnings release: Q4 2025

Feb 5, 2026, 7:00 AM EST - 7 months ago

Ocular Therapeutix Earnings release: Q4 2025


Ocular Therapeutix Earnings Call Transcript: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Ocular Therapeutix Earnings Call Transcript: Q3 2025


Ocular Therapeutix Quarterly report: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Ocular Therapeutix Quarterly report: Q3 2025


Ocular Therapeutix Earnings release: Q3 2025

Nov 4, 2025, 8:00 AM EST - 10 months ago

Ocular Therapeutix Earnings release: Q3 2025


Ocular Therapeutix Transcript: Investor Day 2025

Sep 30, 2025, 2:00 PM EDT - 11 months ago

Ocular Therapeutix Transcript: Investor Day 2025


Ocular Therapeutix Press release: FY 2025

Sep 30, 2025, 2:00 PM EDT - 11 months ago

Ocular Therapeutix Press release: FY 2025


Ocular Therapeutix Slides: FY 2025

Sep 30, 2025, 2:00 PM EDT - 11 months ago

Ocular Therapeutix Slides: FY 2025


Ocular Therapeutix Slides: FY 2025

Sep 19, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Slides: FY 2025


Ocular Therapeutix Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q2 2025


Ocular Therapeutix Quarterly report: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Quarterly report: Q2 2025


Ocular Therapeutix Earnings release: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings release: Q2 2025


Ocular Therapeutix Slides: FY 2025

Jun 23, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Slides: FY 2025


Ocular Therapeutix Slides: FY 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Slides: FY 2025


Ocular Therapeutix Quarterly report: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Quarterly report: Q1 2025


Ocular Therapeutix Earnings release: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

Ocular Therapeutix Earnings release: Q1 2025


Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing


Ocular Therapeutix Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing


Ocular Therapeutix Proxy statement: Proxy Filing

Apr 18, 2025, 8:00 AM EDT - 1 year ago

Ocular Therapeutix Proxy statement: Proxy Filing


Ocular Therapeutix Slides: Corporate Presentation

Mar 27, 2025, 7:00 PM EDT - 1 year ago

Ocular Therapeutix Slides: Corporate Presentation


Ocular Therapeutix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q4 2024


Ocular Therapeutix Annual report: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Annual report: Q4 2024


Ocular Therapeutix Earnings release: Q4 2024

Mar 3, 2025, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q4 2024


Ocular Therapeutix Earnings Call Transcript: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings Call Transcript: Q3 2024


Ocular Therapeutix Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Quarterly report: Q3 2024


Ocular Therapeutix Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Ocular Therapeutix Earnings release: Q3 2024


Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day

Oct 2, 2024, 3:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: UBS Virtual Ophthalmology Day


Ocular Therapeutix™ to Present at September Retina Meetings

Sep 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix™ to Present at September Retina Meetings


Ocular Therapeutix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Earnings Call Transcript: Q2 2024


Ocular Therapeutix Quarterly report: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Quarterly report: Q2 2024


Ocular Therapeutix Earnings release: Q2 2024

Aug 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Earnings release: Q2 2024


Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 2 years ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results


Ocular Therapeutix Transcript: Investor Day 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Transcript: Investor Day 2024


Ocular Therapeutix Slides: FY 2024

Jun 13, 2024, 2:00 PM EDT - 2 years ago

Ocular Therapeutix Slides: FY 2024


Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 2 years ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024


Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 2 years ago

Ocular Therapeutix™ Reports First Quarter 2024 Results


Ocular Therapeutix Quarterly report: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Quarterly report: Q1 2024


Ocular Therapeutix Earnings release: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Ocular Therapeutix Earnings release: Q1 2024


Ocular Therapeutix Proxy statement: Proxy Filing

May 7, 2024, 8:00 AM EDT - 2 years ago

Ocular Therapeutix Proxy statement: Proxy Filing


highkick
highkick Aug. 24 at 3:40 PM
$OCUL 11k 9$ puts and 12k 11 $ calls for September 18th coming into play ?
0 · Reply
DrKyle
DrKyle Aug. 24 at 3:30 PM
$OCUL pending legal investigation into Eyepoint Pharmaceuticals https://www.globenewswire.com/news-release/2026/08/24/3349866/3080/en/levi-korsinsky-notifies-investors-of-pending-investigation-into-securities-claims-involving-eyepoint-pharmaceuticals-eypt.html
1 · Reply
MaxKlim
MaxKlim Aug. 24 at 3:11 PM
$OCUL time to add
0 · Reply
Tmoney85285
Tmoney85285 Aug. 24 at 3:07 PM
$OCUL hahahahahahahhaaha
0 · Reply
Tmoney85285
Tmoney85285 Aug. 24 at 1:52 PM
$OCUL hahahaha well deserved you losers. TKIs work about as well as JJ on a diet! LMAO
1 · Reply
Kashking03
Kashking03 Aug. 24 at 10:47 AM
$OCUL does this brk 12$ this week or dip to single digit 🫣 @ShortSuckieTuckie @Harvo
2 · Reply
Aaronpell
Aaronpell Aug. 24 at 3:50 AM
0 · Reply
esu89
esu89 Aug. 23 at 10:53 PM
$OCUL for all those waiting for a buyout, IMO, it ain’t happening soon. I believe that this Board and management team and their investment, financial and legal advisers are shooting for the stars. I think they feel really strong about and are very confident in what they have. They are going to commercialize Axpaxli for wetAMD, start selling it and wait for the for the top line results from NPDR phase 3 before they would get the kind of interest they think they deserve. That being said, I think they have to give strong consideration right now to anything at $6 billion or more. What I think they are really looking for is $10 to $15 billion in the back half of 2027 or beyond. The real question for each investor is what their objective is. Anyone that doesn’t have an objective and sale plan right now is foolish IMO. As to an international partnership(s), not a chance unless all prospects of being acquired disappear. Just my thoughts.
2 · Reply
ShortSuckieTuckie
ShortSuckieTuckie Aug. 23 at 5:45 PM
$OCUL Important events as I see it coming down the road 1. Filing of the NDA with the added SOL-R interim safety data which will include some redosed patients. If we get the "no new or unexpected safety events were identified in the Sol-R safety data" that is an important de-risking event regarding redosing. 2. SOL-1 2-year safety extension study mid 2027 adds to the data more redosing patients to give the FDA a level of comfort with redosing on the label. 3. SOL-R in mid 2028 which "could" give Axpaxli a superiority label versus Eylea HD. Looking at SOL-1 and Pulsar data, I feel pretty good about this happening. The genius of extending this trial puts the last data point at a few weeks before the next scheduled injection. I could be wrong, but given Pravin's comment that SOL-R is needed for ExUS markets, I would place the chances of an acquisition ahead of a ExUS Partnership with significant CVR's for SOL-R and Helios3. Then again, what's $350M for big pharma.
3 · Reply
Kashking03
Kashking03 Aug. 22 at 11:00 PM
$OCUL Summary of $OCUL piper discussion: > what about $EYPT Failed study move on > well could there be any relation to GA or glaucoma? Impossible, without a shadow of doubt > how does it affect you? We are better in every dimension across every parameter > guidance for your upcoming data or margin on effect or other parameters It will succeed but no guidance If ocular every does not hit a trial endpoint or faces bad clinical results, I hope they approach it to the bar that they are holding $EYPT to I am no expert in retinal diseases, and I also share the view that excluding outliers in such a trial is not a viable approach, but I am curious what association if any is there between tki in this setting and GA and glaucoma.
0 · Reply
WarrenDouglasTrader
WarrenDouglasTrader Aug. 22 at 10:20 PM
$OCUL Most obvious buyout target Ive ever seen and yet.....where are the suitors!!!!! Cmon people, $20-25 buyout and call it a day.
2 · Reply
Shipping2004
Shipping2004 Aug. 22 at 12:45 PM
$OCUL 30% up in one month. Hey Ttttttt.....many. how your shorts are working?
2 · Reply
Dy2ski
Dy2ski Aug. 22 at 1:24 AM
$OCUL Looks like the courts DENIED Eyepoint's Lawsuit Preliminary Injunction today! Also read in the docket that Ocular filed Supplemental Evidence (08.18.26)showing that Eyepoint was basically full of crap trying to blame Ocular for their "inability" to raise capital when they've been hitting their ATM hard this month. Probably, helped with PI denial. I can see why CEO Dugel is fired up...Eyepoint turning into sleazebags.
2 · Reply
esu89
esu89 Aug. 21 at 9:32 PM
$OCUL I rarely block anyone as I try and give everyone the benefit of the doubt that they might have something to say that would be useful to me. I defintely like reading posts that are contrary to my understanding of a situation/business. I probably pay my more attention to differing views than I do those of posters who agree with me. It’s a helpful sanity check. That being said, I finally blocked @moneybagged the poster of coffin and funeral gifs, @TickrTalk0007 poster of stuff he makes up as factual that is simply wrong and the biggest dipshit of all @Tmoney85285 who claims to have 137,000 shares short right now who can’t keep his lies straight, always sells at the very top and buys at the very low and doesn’t acknowledge one iota of risk in his made up short position. These posters are never going to provide me any information I may find useful. Know what you own and good luck to all.
3 · Reply
Tmoney85285
Tmoney85285 Aug. 21 at 8:30 PM
$OCUL god the fucking obese whale is exhausting. he does not understand that $EYPT falling flat on their face should be good, but its not! hes a fucking idiot, which is why im glad im on the other side of this. TKIs are like the Challenger- dead at liftoff!
1 · Reply
MaxKlim
MaxKlim Aug. 21 at 7:58 PM
$OCUL https://x.com/semodough/status/2090877010373394602?s=46
0 · Reply
Tmoney85285
Tmoney85285 Aug. 21 at 7:41 PM
$OCUL hahahahaha you guys fucking suck!
1 · Reply
svertical1
svertical1 Aug. 21 at 7:09 PM
$OCUL Upper channel test, we’ll see if holds.
3 · Reply
Tmoney85285
Tmoney85285 Aug. 21 at 6:41 PM
$OCUL LMAO! this aged well! what a moron. probably a JJ burner!
1 · Reply
MasterChiefCov
MasterChiefCov Aug. 21 at 5:32 PM
$EYPT @DrKyle Funny how much energy you're spending bashing EYPTs and retail flippers while completely ignoring your own massive bias. Everyone knows you're probably heavily exposed to $OCUL, let's see how quiet you get when the LUCIA Phase 3 data drops later this year just like you were when it was pumping on Wednesday.
8 · Reply
Aaronpell
Aaronpell Aug. 21 at 5:18 PM
$OCUL wants to run, someone is holding it back.
0 · Reply
svertical1
svertical1 Aug. 21 at 2:43 PM
$OCUL Nice breakout!
0 · Reply